Abstract 495P
Background
Osimertinib has been established as standard treatment for patients with advanced EGFR-mutated NSCLC. We assessed the clinical relevance of EGFR mutation tracking in plasma circulating tumor DNA (ctDNA) after initiation of osimertinib therapy in patients who were pre-treated with EGFR-tyrosine kinase inhibitors (TKIs).
Methods
Plasma samples of 106 patients with advanced EGFR-mutated NSCLC who received second-line osimertinib after detection of T790M mutation in plasma ctDNA and/or tissue re-biopsy were collected under osimertinib therapy. Plasma ctDNA was tested for EGFR deletions in exon 19, L858R, L861Q, S768I, T790M and C797S mutations using droplet digital PCR (ddPCR). Primary endpoint was progression-free survival (PFS). Univariate and multivariable Cox proportional hazard models were used to evaluate the risk of progression.
Results
In 57 out of 106 patients plasma samples were available within the first 8 weeks after osimertinib therapy initiation. Within this time frame, the activating mutation remained detectable in plasma of 19/57 patients (33%) and the T790M mutation in 8/57 patients (14%). The C797S mutation was not detectable within 8 weeks after osimertinib start. Patients with persistence of the activating EGFR mutation in plasma ctDNA within 8 weeks after osimertinib initiation had a shorter PFS compared to patients who had lost the activating EGFR mutation (median PFS 3.4 versus 26.9 months; hazard ratio [HR] 6.17, 95% confidence interval [CI] 3.03-12.56, p < 0.0001). Similarly, detection of T790M in plasma ctDNA was also associated with shorter PFS (median PFS 7.0 versus 19.0 months; HR 2.32, 95% CI 1.00-5.37, p = 0.05). Multivariable analysis using a stepwise backward elimination model demonstrated that persistence of activating EGFR mutations and T790M in plasma ctDNA remained significant predictors of shorter PFS after adjusting for clinical parameters and T790M.
Conclusions
Our results show that tracking of activating EGFR mutations during osimertinib therapy is clinically relevant. Detection of activating EGFR mutations in plasma ctDNA 8 weeks after osimertinib initiation predicts shorter PFS of second-line treatment with osimertinib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
A. Buder: Honoraria (self): AstraZeneca. M.J. Hochmair: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim. M. Filipits: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer
Presenter: Jong Hoon Lee
Session: Poster display session
Resources:
Abstract
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract